NCT00217022View on ClinicalTrials.gov

Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Lymphocytic ColitisDiarrhea

Interventions

OTHER

Placebo

Placebo, 3 tablets daily

DRUG

Budesonide

9 mg daily (three tablets)

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER